Search

Your search keyword '"Leiter LA"' showing total 638 results

Search Constraints

Start Over You searched for: Author "Leiter LA" Remove constraint Author: "Leiter LA"
638 results on '"Leiter LA"'

Search Results

1. Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada

6. Association of Low- and No-Calorie Sweetened Beverages as a Replacement for Sugar-Sweetened Beverages With Body Weight and Cardiometabolic Risk: A Systematic Review and Meta-analysis

7. Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies

8. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

9. Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials

10. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

11. Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers - a pre-specified analysis from ORION-1

12. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

13. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study

14. Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke

15. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial

16. Inflammatory and cholesterol risk in the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in patients with elevated risk)

18. Evolocumab and clinical outcomes in patients with cardiovascular disease

19. Inclisiran in patients with high CV risk and elevated LDL-cholesterol

20. Evolocumab and clinical outcomes in patients with cardiovascular disease

22. Ausgangscharakteristika der DECLARE-TIMI-58-Studienpopulation

25. Aldosterone does not predict cardiovascular events following acute coronary syndrome in patients initially without heart failure

26. LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial

27. Corrigendum to: Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI)

28. What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management

29. Personalized Management in Type 2 Diabetes

30. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

32. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes

34. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

40. Effect of fructose on glycemic control in diabetes: a systematic review and meta-analysis of controlled feeding trials.

41. Effect of fructose on blood pressure: a systematic review and meta-analysis of controlled feeding trials.

42. Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis.

43. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial.

44. Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin.

45. Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?

46. Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial.

48. AUDIT study. Evidence of global undertreatment of dyslipidaemia in patient with type 2 diabetes mellitus.

49. ß-cell preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes.

50. Defining the role of statins in diabetes.

Catalog

Books, media, physical & digital resources